Shionogi
SGIOF · Osaka, Japan
Works in Cardiovascular · Genetic & rare · GI & liver · Hematology · Immunology · Infectious disease · Metabolic & endocrine · Neurology · Oncology · Psychiatry · Renal & urogenital · Respiratory · Women's health
Shionogi is a clinical trial sponsor based in Osaka, Japan, listed as SGIOF. It has 12 active clinical trials with 4,066 planned participants, across 13 therapeutic areas. Since 2021 it has completed 51 trials and stopped 7 early.
Trial track record · since 2021
Financials · SGIOF
Pipeline · 12 active trials
| Stage | Trial | Status |
|---|---|---|
On the market
3 approved drug applications with a product on the market.
Questions about Shionogi
Shionogi is lead sponsor of 12 active clinical trials on ClinicalTrials.gov, with 4,066 planned participants, in Cardiovascular, Genetic & rare, GI & liver, Hematology and other areas. Since 2021 it has completed 51 trials and stopped 7 early.
Shionogi is based in Osaka, Japan and is listed as SGIOF. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Shionogi; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-16.
Approve Suite is not affiliated with Shionogi. Informational only.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.